Up-regulation of amino acid transporter SLC6A19 activity and surface protein abundance by PKB/Akt and PIKfyve

Cellular Physiology and Biochemistry

Volumn 30, Issue 6, 2012, Pages 1538-1546

  Bogatikov, Evgenii ^a   Munoz, Carlos ^a   Pakladok, Tatsiana ^a   Alesutan, Ioana ^a   Shojaiefard, Manzar ^a,f   Seebohm, Guiscard ^e   Föller, Michael ^a,b   Palmada, Monica ^d   Böhmer, Christoph ^d   Bröer, Stefan ^c   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^d RHINE WAAL UNIVERSITY OF APPLIED SCIENCES   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amino acid uptake; PIKfyve; PKB Akt

Indexed keywords

AMINO ACID TRANSPORTER; BREFELDIN A; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PROTEIN KINASE B; SLC6A19; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ARTICLE; ELECTRODE; ENZYME ACTIVITY; ENZYME INDUCTION; GENE CONSTRUCT; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VOLTAGE CLAMP; XENOPUS;

EID: 84870749150     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000343341     Document Type: Article

References (59)

1. Bohmer C, Broer A, Munzinger M, Kowalczuk S, Rasko JE, Lang F, Broer S: Characterization of mouse amino acid transporter B0AT1 (slc6a19). Biochem J 2005;389:745-751. (Pubitemid 41117335)
2. Broer S, Bailey CG, Kowalczuk S, Ng C, Vanslambrouck JM, Rodgers H, Auray-Blais C, Cavanaugh JA, Broer A, Rasko JE: Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters. J Clin Invest 2008;118:3881-3892.
3. Broer S: The role of the neutral amino acid transporter B0AT1 (SLC6A19) in Hartnup disorder and protein nutrition. IUBMB Life 2009;61:591-599.
4. Verrey F, Singer D, Ramadan T, Vuille-dit-Bille RN, Mariotta L, Camargo SM: Kidney amino acid transport. Pflugers Arch 2009;458:53-60.
5. Cheon CK, Lee BH, Ko JM, Kim HJ, Yoo HW: Novel mutation in SLC6A19 causing late-onset seizures in Hartnup disorder. Pediatr Neurol 2010;42:369-371.
6. Kleta R, Romeo E, Ristic Z, Ohura T, Stuart C, Arcos-Burgos M, Dave MH, Wagner CA, Camargo SR, Inoue S, Matsuura N, Helip-Wooley A, Bockenhauer D, Warth R, Bernardini I, Visser G, Eggermann T, Lee P, Chairoungdua A, Jutabha P, Babu E, Nilwarangkoon S, Anzai N, Kanai Y, Verrey F, Gahl WA, Koizumi A: Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet 2004;36:999-1002. (Pubitemid 39167498)
7. Seow HF, Broer S, Broer A, Bailey CG, Potter SJ, Cavanaugh JA, Rasko JE: Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat Genet 2004;36:1003-1007. (Pubitemid 39167499)
8. Bohmer C, Sopjani M, Klaus F, Lindner R, Laufer J, Jeyaraj S, Lang F, Palmada M: The serum and glucocorticoid inducible kinases SGK1-3 stimulate the neutral amino acid transporter SLC6A19. Cell Physiol Biochem 2010;25:723-732.
9. Boehmer C, Okur F, Setiawan I, Broer S, Lang F: Properties and regulation of glutamine transporter SN1 by protein kinases SGK and PKB. Biochem Biophys Res Commun 2003;306:156-162. (Pubitemid 36629420)
10. Boehmer C, Rajamanickam J, Schniepp R, Kohler K, Wulff P, Kuhl D, Palmada M, Lang F: Regulation of the excitatory amino acid transporter EAAT5 by the serum and glucocorticoid dependent kinases SGK1 and SGK3. Biochem Biophys Res Commun 2005;329:738-742. (Pubitemid 40311805)
11. Boehmer C, Palmada M, Rajamanickam J, Schniepp R, Amara S, Lang F: Post-translational regulation of EAAT2 function by co-expressed ubiquitin ligase Nedd4-2 is impacted by SGK kinases. J Neurochem 2006;97:911-921.
12. Bohmer C, Philippin M, Rajamanickam J, Mack A, Broer S, Palmada M, Lang F: Stimulation of the EAAT4 glutamate transporter by SGK protein kinase isoforms and PKB. Biochem Biophys Res Commun 2004;324:1242-1248. (Pubitemid 40292156)
13. Green CJ, Goransson O, Kular GS, Leslie NR, Gray A, Alessi DR, Sakamoto K, Hundal HS: Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J Biol Chem 2008;283:27653-27667.
14. Palmada M, Speil A, Jeyaraj S, Bohmer C, Lang F: The serine/threonine kinases SGK1, 3 and PKB stimulate the amino acid transporter ASCT2. Biochem Biophys Res Commun 2005;331:272-277. (Pubitemid 40545172)
15. Schniepp R, Kohler K, Ladewig T, Guenther E, Henke G, Palmada M, Boehmer C, Rothstein JD, Broer S, Lang F: Retinal colocalization and in vitro interaction of the glutamate transporter EAAT3 and the serum-and glucocorticoid-inducible kinase SGK1 [correction]. Invest Ophthalmol Vis Sci 2004;45:1442-1449. (Pubitemid 38859323)
16. Shojaiefard M, Christie DL, Lang F: Stimulation of the creatine transporter SLC6A8 by the protein kinases SGK1 and SGK3. Biochem Biophys Res Commun 2005;334:742-746. (Pubitemid 41033184)
17. Ikonomov OC, Sbrissa D, Mlak K, Kanzaki M, Pessin J, Shisheva A: Functional dissection of lipid and protein kinase signals of PIKfyve reveals the role of PtdIns 3, 5-P2 production for endomembrane integrity. J Biol Chem 2002;277:9206-9211. (Pubitemid 34953000)
18. Sbrissa D, Ikonomov OC, Shisheva A: PIKfyve, a mammalian ortholog of yeast Fab1p lipid kinase, synthesizes 5-phosphoinositides. Effect of insulin. J Biol Chem 1999;274:21589-21597.
19. Sbrissa D, Ikonomov OC, Deeb R, Shisheva A: Phosphatidylinositol 5-phosphate biosynthesis is linked to PIKfyve and is involved in osmotic response pathway in mammalian cells. J Biol Chem 2002;277:47276-47284. (Pubitemid 36159239)
20. Sbrissa D, Ikonomov OC, Strakova J, Shisheva A: Role for a novel signaling intermediate, phosphatidylinositol 5-phosphate, in insulin-regulated F-actin stress fiber breakdown and GLUT4 translocation. Endocrinology 2004;145:4853-4865. (Pubitemid 39551102)
21. Ikonomov OC, Sbrissa D, Shisheva A: Mammalian cell morphology and endocytic membrane homeostasis require enzymatically active phosphoinositide 5-kinase PIKfyve. J Biol Chem 2001;276:26141-26147.
22. Ikonomov OC, Sbrissa D, Foti M, Carpentier JL, Shisheva A: PIKfyve controls fluid phase endocytosis but not recycling/degradation of endocytosed receptors or sorting of procathepsin D by regulating multivesicular body morphogenesis. Mol Biol Cell 2003;14:4581-4591. (Pubitemid 37444657)
23. Ikonomov OC, Sbrissa D, Shisheva A: Localized PtdIns 3, 5-P2 synthesis to regulate early endosome dynamics and fusion. Am J Physiol Cell Physiol 2006;291:C393-C404. (Pubitemid 44148163)
24. Rusten TE, Rodahl LM, Pattni K, Englund C, Samakovlis C, Dove S, Brech A, Stenmark H: Fab1 phosphatidylinositol 3-phosphate 5-kinase controls trafficking but not silencing of endocytosed receptors. Mol Biol Cell 2006;17:3989-4001. (Pubitemid 44330882)
25. Rutherford AC, Traer C, Wassmer T, Pattni K, Bujny MV, Carlton JG, Stenmark H, Cullen PJ: The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport. J Cell Sci 2006;119:3944-3957. (Pubitemid 44650868)
26. Berwick DC, Dell GC, Welsh GI, Heesom KJ, Hers I, Fletcher LM, Cooke FT, Tavare JM: Protein kinase B phosphorylation of PIKfyve regulates the trafficking of GLUT4 vesicles. J Cell Sci 2004;117:5985-5993. (Pubitemid 40123965)
27. Watson RT, Pessin JE: Bridging the GAP between insulin signaling and GLUT4 translocation. Trends Biochem Sci 2006;31:215-222.
28. Welsh GI, Hers I, Berwick DC, Dell G, Wherlock M, Birkin R, Leney S, Tavare JM: Role of protein kinase B in insulin-regulated glucose uptake. Biochem Soc Trans 2005;33:346-349. (Pubitemid 40604369)
29. Shojaiefard M, Strutz-Seebohm N, Tavare JM, Seebohm G, Lang F: Regulation of the Na (+), glucose cotransporter by PIKfyve and the serum and glucocorticoid inducible kinase SGK1. Biochem Biophys Res Commun 2007;359:843-847. (Pubitemid 46946895)
30. Seebohm G, Strutz-Seebohm N, Birkin R, Dell G, Bucci C, Spinosa MR, Baltaev R, Mack AF, Korniychuk G, Choudhury A, Marks D, Pagano RE, Attali B, Pfeufer A, Kass RS, Sanguinetti MC, Tavare JM, Lang F: Regulation of endocytic recycling of KCNQ1/KCNE1 potassium channels. Circ Res 2007;100:686-692. (Pubitemid 46594883)
31. Gehring EM, Lam RS, Siraskar G, Koutsouki E, Seebohm G, Ureche ON, Ureche L, Baltaev R, Tavare JM, Lang F: PIKfyve upregulates CFTR activity. Biochem Biophys Res Commun 2009;390:952-957.
32. Klaus F, Laufer J, Czarkowski K, Strutz-Seebohm N, Seebohm G, Lang F: PIKfyve-dependent regulation of the Cl-channel ClC-2. Biochem Biophys Res Commun 2009;381:407-411.
33. Sopjani M, Kunert A, Czarkowski K, Klaus F, Laufer J, Foller M, Lang F: Regulation of the Ca (2+) channel TRPV6 by the kinases SGK1, PKB/Akt, and PIKfyve. J Membr Biol 2010;233:35-41.
34. Alesutan IS, Ureche ON, Laufer J, Klaus F, Zurn A, Lindner R, Strutz-Seebohm N, Tavare JM, Boehmer C, Palmada M, Lang UE, Seebohm G, Lang F: Regulation of the glutamate transporter EAAT4 by PIKfyve. Cell Physiol Biochem 2010;25:187-194.
35. Gehring EM, Zurn A, Klaus F, Laufer J, Sopjani M, Lindner R, Strutz-Seebohm N, Tavare JM, Boehmer C, Palmada M, Lang UE, Seebohm G, Lang F: Regulation of the glutamate transporter EAAT2 by PIKfyve. Cell Physiol Biochem 2009;24:361-368.
36. Seebohm G, Strutz-Seebohm N, Baltaev R, Korniychuk G, Knirsch M, Engel J, Lang F: Regulation of KCNQ4 potassium channel prepulse dependence and current amplitude by SGK1 in Xenopus oocytes. Cell Physiol Biochem 2005;16:255-262. (Pubitemid 41643025)
37. Rexhepaj R, Dermaku-Sopjani M, Gehring EM, Sopjani M, Kempe DS, Foller M, Lang F: Stimulation of electrogenic glucose transport by glycogen synthase kinase 3. Cell Physiol Biochem 2010;26:641-646.
38. Hosseinzadeh Z, Bhavsar SK, Sopjani M, Alesutan I, Saxena A, Dermaku-Sopjani M, Lang F: Regulation of the glutamate transporters by JAK2. Cell Physiol Biochem 2011;28:693-702.
39. Dermaku-Sopjani M, Sopjani M, Saxena A, Shojaiefard M, Bogatikov E, Alesutan I, Eichenmuller M, Lang F: Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. Cell Physiol Biochem 2011;28:251-258.
40. Camargo SM, Singer D, Makrides V, Huggel K, Pos KM, Wagner CA, Kuba K, Danilczyk U, Skovby F, Kleta R, Penninger JM, Verrey F: Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. Gastroenterology 2009;136:872-882.
41. Danilczyk U, Sarao R, Remy C, Benabbas C, Stange G, Richter A, Arya S, Pospisilik JA, Singer D, Camargo SM, Makrides V, Ramadan T, Verrey F, Wagner CA, Penninger JM: Essential role for collectrin in renal amino acid transport. Nature 2006;444:1088-1091. (Pubitemid 46018530)
42. Kowalczuk S, Broer A, Tietze N, Vanslambrouck JM, Rasko JE, Broer S: A protein complex in the brushborder membrane explains a Hartnup disorder allele. FASEB J 2008;22:2880-2887.
43. Lang F, Busch GL, Ritter M, Volkl H, Waldegger S, Gulbins E, Haussinger D: Functional significance of cell volume regulatory mechanisms. Physiol Rev 1998;78:247-306. (Pubitemid 28070981)
44. Rodriguez J, Vernus B, Toubiana M, Jublanc E, Tintignac L, Leibovitch S, Bonnieu A: Myostatin inactivation increases myotube size through regulation of translational initiation machinery. J Cell Biochem 2011;
45. Bhandaru M, Yang W, Rotte A, Pasham V, Lang F: Regulation of Na (+)/H (+) exchanger in dendritic cells by Akt2. Pflugers Arch 2011;
46. McGivan JD, Bungard CI: The transport of glutamine into mammalian cells. Front Biosci 2007;12:874-882. (Pubitemid 46846863)
47. Medina MA: Glutamine and cancer. J Nutr 2001;131:2539S-2542S. (Pubitemid 32851001)
48. Ganapathy V, Thangaraju M, Prasad PD: Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009;121:29-40.
49. Nakanishi T, Tamai I: Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. J Pharm Sci 2011;100:3731-3750.
50. Fuchs BC, Bode BP: Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005;15:254-266. (Pubitemid 41065034)
51. Carnero A: The PKB/AKT pathway in cancer. Curr Pharm Des 2010;16:34-44.
52. Chin YR, Toker A: Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adh Migr 2011;5:211-214.
53. Ching CB, Hansel DE: Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest 2010;90:1406-1414.
54. Dienstmann R, Rodon J, Markman B, Tabernero J: Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2. Recent Pat Anticancer Drug Discov 2011;6:210-236.
55. Dillon RL, Muller WJ: Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 2010;70:4260-4264.
56. Georgescu MM: PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer 2010;1:1170-1177.
57. Martelli AM, Evangelisti C, Follo MY, Ramazzotti G, Fini M, Giardino R, Manzoli L, McCubrey JA, Cocco L: Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells. Curr Med Chem 2011;18:2715-2726.
58. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Basecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011;3:192-222.
59. Viglietto G, Amodio N, Malanga D, Scrima M, De Marco C: Contribution of PKB/AKT signaling to thyroid cancer. Front Biosci 2011;16:1461-1487.